The Technical Analyst
Arcturus Therapeutics [ARCT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Arcturus Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.29% $25.98
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 699.26 mill |
| EPS: | -1.120 |
| P/E: | -23.20 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 26.92 mill |
| Avg Daily Volume: | 0.483 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -23.20 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -3.95x |
| Company: PE -23.20 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 23.87 - 28.09 ( +/- 8.11%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-25 | Chivukula Pad | Sell | 17 435 | Common Stock |
| 2024-03-19 | Chivukula Pad | Sell | 8 565 | Common Stock |
| 2023-12-15 | Sassine Andy | Buy | 75 000 | Employee Stock Option (right to buy) |
| 2023-12-15 | Chivukula Pad | Buy | 125 000 | Employee Stock Option (right to buy) |
| 2023-12-15 | Kurata Lance | Buy | 75 000 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 78.30 |
| Last 97 transactions |
| Buy: 2 555 134 | Sell: 1 046 972 |
Forecast:
16:00 - $26.00
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $26.00
Forecast 2: 16:00 - $26.00
Forecast 3: 16:00 - $26.00
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $25.98 (-1.29% ) |
| Volume | 0.622 mill |
| Avg. Vol. | 0.483 mill |
| % of Avg. Vol | 128.75 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ARCT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $38.39 | N/A | Active |
|---|
ARCT
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Latest Press Releases
2024-03-07 16:01:00 - Press Release
Arcturus Therapeutics Announces Fourth Quarter And Fiscal Year 2023 Financial Update And Pipeline Progress
San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth quarter ended december 31, 2023, and provided corporate updates. “i am excited about the continued pipeline progress and efforts toward commercialization achieved by arcturus in.
2024-02-26 09:00:00 - Press Release
Arcturus Therapeutics To Present At The Barclays 26th Annual Global Healthcare Conference
San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the company will present at a fireside chat hosted by barclays 26th annual global healthcare conference in miami, on thursday, march 14, 2024, at 11:45 a.m. eastern time. a webcast and repla.
2024-02-22 08:30:00 - Press Release
Arcturus Therapeutics Receives Orphan Medicinal Product Designation From The European Commission (ec), For Arct-032, For The Treatment Of Cystic Fibrosis
San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that the european commission (ec), based on a positive opinion issued by the european medicines agency (ema), has granted orphan medicinal product designation for the com.
2024-02-05 08:30:00 - Press Release
New Covid-19 Sa-mrna Results From Csl And Arcturus Therapeutics Demonstrate Longer Duration Of Immunity Compared To Conventional Covid-19 Mrna Vaccine Booster
King of prussia, pa. & san diego--(business wire)---- $arct #clinicaltrial--global biotechnology leader csl (asx:csl; usotc:cslly) and arcturus therapeutics (nasdaq: arct) today announced the results of a follow-up analysis of a phase 3 study evaluating a booster dose of arct-154, the world's first approved self-amplifying messenger rna (sa-mrna) covid-19 vaccine, compared to a conventional mrna covid-19 vaccine. arct-154 was administered at one-sixth the dose of comirnaty® (5 Μg vs 30 Μg, respectively). the new analys.
2023-12-21 08:00:00 - Press Release
Csl And Arcturus Therapeutics' Arct-154 Demonstrates Non-inferiority To Original Strain And Superior Immunogenicity To Omicron Ba.4/5 Variant Compared To First-generation Mrna Vaccine Booster
King of prussia, pa. & san diego--(business wire)---- $arct #clinicaltrial--global biotechnology leader csl (asx:csl; usotc:cslly) and arcturus therapeutics (nasdaq: arct) today announced the publication in lancet infectious diseases of a phase 3 study showing that a booster dose of arct-154, a novel, self-amplifying messenger rna (sa-mrna) vaccine, elicited a numerically higher immune response (meeting the non-inferiority criteria) against the original wuhan-hu-1 virus strain, and a superior immune response against om.
Latest News
2024-03-07 18:32:11 - Seeking Alpha
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations & Marketing. Joe Payne - President & Chief Executive Officer Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer & Chief Operating Officer Conference Call Participants Evan Wang - Guggenheim Securities Whitney Ijem - Canaccord Genuity Myles Minter - William Blair Jan Hughes - Wells Fargo Pete Stavropoulos - Cantor Fitzgerald Thomas Yip - H.C.
2024-03-07 18:11:11 - Zacks Investment Research
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $1.69. This compares to earnings of $4.33 per share a year ago.
2024-03-04 14:26:07 - Zacks Investment Research
Arcturus (ARCT) Stock Surges 73% in 3 Months: Here's Why
Arcturus' (ARCT) steady progress with its product candidate, ARCT-032, for the treatment of cystic fibrosis is encouraging.
2024-02-26 15:20:23 - InvestorPlace
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
2024-02-21 13:04:28 - InvestorPlace
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Biotech stocks are often at the forefront of innovation. These are the companies we hear about that are driving breakthroughs in healthcare.
2024-02-20 16:39:09 - InvestorPlace
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
We've all heard the story with AI by now, and for good reason. It has massive potential to overhaul almost every aspect of our lives.
2024-02-02 11:25:32 - Seeking Alpha
Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments
Arcturus Therapeutics is a biotechnology company specializing in rare and infectious diseases, with approved COVID and influenza vaccines in Japan and the EU. The company is developing game-changing therapies for Ornithine Transcarbamylase Deficiency and Cystic Fibrosis. Despite trading at a slight premium relative to peers, ARCT's investment appeal is supported by its innovative IP, financial health, and clinical trials.
2024-01-31 17:20:05 - Seeking Alpha
Arcturus: H1 2024 Rare Disease Drug Data On Deck
Arcturus Therapeutics Holdings Inc. interim results from the phase 1b study, using ARCT-032 for the treatment of patients with Cystic Fibrosis, are expected in the 1st half of 2024. The global Cystic Fibrosis market is projected to grow to $12.9 billion by 2030. Interim results from the phase 2 study, using ARCT-810 for the treatment of patients with OTC Deficiency, are expected in the 1st half of 2024.
2023-12-17 12:03:57 - InvestorPlace
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital ecosystem, society will continue to invest in clinical breakthrough stocks in the hopes of forwarding treatments to vexing conditions and diseases.
2023-12-13 22:39:18 - InvestorPlace
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and how we can improve functioning within the body.